The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacokinetics and pharmacodynamics evaluation in phase I trial of APX-343A, selective NOX inhibitor targeting CAF-mediated immunosuppression in patients with advanced solid tumors.
 
Sung Hwan Moon
Employment - Aptabio Therapeutics
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BeOne (Inst); Beringer Ingelheim (Inst); Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Jazz Pharmaceuticals (Inst); Lilly; MSD Oncology; Roche/Genentech; Sillajen
 
Hei-Cheul Jeung
No Relationships to Disclose
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Celltrion; Merck KGaA; MSD Oncology; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; PIN therapeutics; Takeda
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avelos Therapeutics (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDRx (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Leap Therapeutics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Torl Biotherapeutics (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Yuhan (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Soo Jin Lee
Employment - Aptabio Therapeutics
 
Yoenhee Ahn
Employment - Aptabio Therapeutics
 
Hyesung Shin
Employment - Aptabio Therapeutics